Julie Krop, M.D. has served as a member of our Board since February 2021. Dr. Krop is currently the Chief Medical Officer of DiaMedica Therapeutics, Inc. (Nasdaq:DMAC), a clinical-stage biopharmaceutical company focused on development of novel treatments for pre-eclampsia, fetal growth restriction, and acute ischemic stroke. Prior to assuming her position at DiaMedica, Dr. Krop was President of JSK Consulting Services from April 2024 to August 2025. From August 2021 through April 2024, Dr. Krop was the Chief Medical Officer of PureTech Health plc (Nasdaq: PRTC), a clinical stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for people living with psychiatric and neurological conditions. Dr. Krop also served as Chief Medical Officer of Freeline Therapeutics (Nasdaq: FRLN), a clinical stage gene therapy company, from April 2020 to August 2021 and was the Chief Medical Officer and Executive Vice President, Development, with AMAG Pharmaceuticals (Nasdaq: AMAG) from 2015 to 2021. From 2012 to 2015, Dr. Krop served as the Vice President, Clinical Development for Vertex Pharmaceuticals (Nasdaq: VRTX). In addition, Dr. Krop was Vice President, Clinical Development and Regulatory Affairs for Stryker Biotech (NYSE: SYK) from 2006 to 2012. Dr. Krop received a B.A. from Brown University and her M.D. from Brown University School of Medicine. She completed her fellowship in the Department of Endocrinology at the Johns Hopkins University School of Medicine, where she was also a Robert Wood Johnson Foundation Clinical Scholar. Our Board believes that Dr. Krop’s extensive experience in successfully designing and executing clinical development programs from early-stage development through FDA approval, and senior leadership roles across clinical development, regulatory affairs, clinical operations, pharmacovigilance, medical affairs and program management during her career in the pharmaceutical and biotechnology industry, as well as her medical background, qualifies her to serve on our Board of Directors.
What is Julie Krop's net worth?
The estimated net worth of Julie Krop is at least $124.88 thousand as of June 23rd, 2026. Krop owns 25,000 shares of Aquestive Therapeutics stock worth more than $124,875 as of June 24th. This net worth approximation does not reflect any other assets that Krop may own. Learn More about Julie Krop's net worth.
How do I contact Julie Krop?
Has Julie Krop been buying or selling shares of Aquestive Therapeutics?
In the last ninety days, Julie Krop has sold $125,500.00 of Aquestive Therapeutics stock. Most recently, Julie Krop sold 25,000 shares of the business's stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $5.02, for a transaction totalling $125,500.00. Following the completion of the sale, the director now directly owns 25,000 shares of the company's stock, valued at $125,500. Learn More on Julie Krop's trading history.
Who are Aquestive Therapeutics' active insiders?
Are insiders buying or selling shares of Aquestive Therapeutics?
In the last year, insiders at the sold shares 17 times. They sold a total of 705,717 shares worth more than $3,503,152.87. The most recent insider tranaction occured on June, 23rd when Director Julie Krop sold 25,000 shares worth more than $125,500.00. Insiders at Aquestive Therapeutics own 6.8% of the company.
Learn More about insider trades at Aquestive Therapeutics. Information on this page was last updated on 6/23/2026.
